Skip to content

Follow-up of Extreme Neonatal Hyperbilirubinemia in 5-10 Year Old Children: a Danish Population Based Study

Follow-up of Extreme Neonatal Hyperbilirubinemia in 5-10 Year Old Children: a Danish Population Based Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01599611
Enrollment
128
Registered
2012-05-16
Start date
2010-03-31
Completion date
2011-01-31
Last updated
2012-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neonatal Hyperbilirubinemia

Keywords

Neonatal hyperbilirubinemia, Follow-up, Motor development, Hearing, Executive function

Brief summary

The objective of this study was to investigate whether infants with total serum bilirubin \> 450 umol/L in the neonatal period and no symptoms or no more than early acute bilirubin encephalopathy develop long term sequelae with impairment of motor development, hearing and executive function compared with a control group.

Detailed description

Children in both the exposed and the non-exposed group were examined by use of the MABC-2 and pure tone audiometry by the responsible examiner for the study, Pernille Vandborg, MD. The aim was to see whether the exposed group suffered any long term sequelae to the extreme neonatal hyperbilirubinemia, i.e. impaired motor development or hearing impairment, compared to a control group. The examinations took place at the local hospital.

Interventions

PROCEDUREMovement assessment battery for children - 2

A standardised test developed to identify developmental difficulties in children.

Sponsors

University of Aarhus
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
5 Years to 10 Years
Healthy volunteers
No

Inclusion criteria

* Gestational age \> 35 weeks * Total serum bilirubin \> 450 umol/L in the neonatal period * Born in the period 01.01.2000 - 31.12.2005

Exclusion criteria

* Acute intermediate or advanced bilirubin encephalopathy

Design outcomes

Primary

MeasureTime frameDescription
Motor developmentAge 5-10 yearsDelayed motor development for children in the exposed group compared to children in the non-exposed group

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026